> top > docs > PMC:7205724 > spans > 17446-18542 > annotations

PMC:7205724 / 17446-18542 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
599 49-54 Species denotes human Tax:9606
613 138-143 Species denotes human Tax:9606
614 328-342 Species denotes Parvovirus B19 Tax:10798
615 389-410 Species denotes Clostridium difficile Tax:1496
616 423-442 Species denotes Mycobacterium avium Tax:1764
617 444-470 Species denotes Mycobacterium tuberculosis Tax:1773
618 199-219 Disease denotes autoimmune disorders MESH:D001327
619 223-252 Disease denotes primary antibody deficiencies MESH:D000081207
620 320-326 Disease denotes sepsis MESH:D018805
621 343-352 Disease denotes infection MESH:D007239
622 364-382 Disease denotes virus encephalitis MESH:D004660
623 411-421 Disease denotes infections MESH:D007239
624 476-495 Disease denotes Nocardia infections MESH:D009617
625 511-521 Disease denotes infections MESH:D007239
633 622-631 Species denotes 2019-nCoV Tax:2697049
634 856-864 Species denotes patients Tax:9606
635 568-576 Species denotes patients Tax:9606
636 661-670 Disease denotes infection MESH:D007239
637 870-877 Disease denotes COVID19 MESH:C000657245
638 996-1003 Disease denotes COVID19 MESH:C000657245
639 1087-1095 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T135 231-239 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T136 384-387 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T137 695-700 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T138 777-780 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T139 785-788 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T140 920-934 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T20 695-700 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T123 199-219 Disease denotes autoimmune disorders http://purl.obolibrary.org/obo/MONDO_0007179
T124 223-252 Disease denotes primary antibody deficiencies http://purl.obolibrary.org/obo/MONDO_0015517
T125 343-352 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T126 364-382 Disease denotes virus encephalitis http://purl.obolibrary.org/obo/MONDO_0006009
T127 370-382 Disease denotes encephalitis http://purl.obolibrary.org/obo/MONDO_0019956
T128 389-421 Disease denotes Clostridium difficile infections http://purl.obolibrary.org/obo/MONDO_0000705
T129 458-470 Disease denotes tuberculosis http://purl.obolibrary.org/obo/MONDO_0018076
T130 476-495 Disease denotes Nocardia infections http://purl.obolibrary.org/obo/MONDO_0017776
T131 511-524 Disease denotes infections in http://purl.obolibrary.org/obo/MONDO_0005550
T132 525-556 Disease denotes primary antibodies deficiencies http://purl.obolibrary.org/obo/MONDO_0015517
T133 661-670 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T134 870-877 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T135 996-1003 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T136 1087-1095 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T217 33-34 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T218 49-54 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T219 125-126 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T220 138-143 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T221 265-268 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T222 339-342 http://purl.obolibrary.org/obo/CLO_0001798 denotes B19
T223 364-369 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T224 608-610 http://purl.obolibrary.org/obo/CLO_0008192 denotes NP
T225 678-680 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T226 808-810 http://purl.obolibrary.org/obo/CLO_0008192 denotes NP
T227 814-816 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T228 846-848 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T156 608-610 Chemical denotes NP http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425
T159 808-810 Chemical denotes NP http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T13 920-934 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T70 144-152 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T71 210-219 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T72 320-326 http://purl.obolibrary.org/obo/IDO_0000636 denotes sepsis
T73 343-352 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T74 364-369 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T75 411-421 http://purl.obolibrary.org/obo/IDO_0000586 denotes infections
T76 485-495 http://purl.obolibrary.org/obo/IDO_0000586 denotes infections
T77 511-524 http://purl.obolibrary.org/obo/IDO_0000586 denotes infections in
T78 661-670 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T79 741-748 http://purl.obolibrary.org/obo/OGMS_0000020 denotes symptom

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T165 49-54 Species denotes human NCBItxid:9606
T166 138-143 Species denotes human NCBItxid:9606
T167 320-326 Species denotes sepsis NCBItxid:137507
T168 328-342 Species denotes Parvovirus B19 NCBItxid:10798
T169 354-369 Species denotes West Nile virus NCBItxid:11082
T170 384-387 Species denotes HIV NCBItxid:57667|NCBItxid:35274|NCBItxid:12721|NCBItxid:11709|NCBItxid:11676
T175 389-410 Species denotes Clostridium difficile NCBItxid:1496
T176 423-442 Species denotes Mycobacterium avium NCBItxid:1764
T177 444-470 Species denotes Mycobacterium tuberculosis NCBItxid:1773
T178 476-484 Species denotes Nocardia NCBItxid:1817
T179 622-631 Species denotes 2019-nCoV NCBItxid:2697049
T180 870-877 Species denotes COVID19 NCBItxid:2697049
T181 996-1003 Species denotes COVID19 NCBItxid:2697049
T182 1087-1095 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T142 0-65 Sentence denotes 4.2.1 Hypothesis: IVIG contains a large pool of human antibodies
T143 66-253 Sentence denotes IVIG is an immunomodulatory treatment currently useful for a variety of human diseases that share an idiopathic origin, ranging from autoimmune disorders to primary antibody deficiencies.
T144 254-562 Sentence denotes Also, IVIG has shown promising results in case of severe (such as sepsis, Parvovirus B19 infection, West Nile virus encephalitis, HIV, Clostridium difficile infections, Mycobacterium avium, Mycobacterium tuberculosis, and Nocardia infections) and recurrent infections in primary antibodies deficiencies [21].
T145 563-682 Sentence denotes Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22].
T146 683-878 Sentence denotes Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19.
T147 879-1004 Sentence denotes Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19.
T148 1005-1096 Sentence denotes It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19.

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T20 695-700 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
599 49-54 Species denotes human Tax:9606
613 138-143 Species denotes human Tax:9606
618 199-219 Disease denotes autoimmune disorders MESH:D001327
619 223-252 Disease denotes primary antibody deficiencies MESH:D000081207
620 320-326 Disease denotes sepsis MESH:D018805
614 328-342 Species denotes Parvovirus B19 Tax:10798
621 343-352 Disease denotes infection MESH:D007239
622 364-382 Disease denotes virus encephalitis MESH:D004660
615 389-410 Species denotes Clostridium difficile Tax:1496
623 411-421 Disease denotes infections MESH:D007239
616 423-442 Species denotes Mycobacterium avium Tax:1764
617 444-470 Species denotes Mycobacterium tuberculosis Tax:1773
624 476-495 Disease denotes Nocardia infections MESH:D009617
625 511-521 Disease denotes infections MESH:D007239
635 568-576 Species denotes patients Tax:9606
633 622-631 Species denotes 2019-nCoV Tax:2697049
636 661-670 Disease denotes infection MESH:D007239
634 856-864 Species denotes patients Tax:9606
637 870-877 Disease denotes COVID19 MESH:C000657245
638 996-1003 Disease denotes COVID19 MESH:C000657245
639 1087-1095 Disease denotes COVID-19 MESH:C000657245

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1970 339-342 Protein denotes B19 https://www.uniprot.org/uniprot/P57058
T1971 615-618 Protein denotes RBD https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022
T1980 830-833 Protein denotes RBD https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T56020 0-5 CD denotes 4.2.1
T95212 7-17 NN denotes Hypothesis
T84611 17-18 -COLON- denotes :
T95417 19-23 NN denotes IVIG
T50853 24-32 VBZ denotes contains
T65863 33-34 DT denotes a
T68527 35-40 JJ denotes large
T83960 41-45 NN denotes pool
T57480 46-48 IN denotes of
T98962 49-54 JJ denotes human
T50450 55-65 NNS denotes antibodies
T12037 66-70 NN denotes IVIG
T52317 71-73 VBZ denotes is
T83276 74-76 DT denotes an
T47689 77-93 JJ denotes immunomodulatory
T32201 94-103 NN denotes treatment
T26744 104-113 RB denotes currently
T6595 114-120 JJ denotes useful
T61951 121-124 IN denotes for
T78252 125-126 DT denotes a
T96672 127-134 NN denotes variety
T75647 135-137 IN denotes of
T64366 138-143 JJ denotes human
T37666 144-152 NNS denotes diseases
T30663 153-157 WDT denotes that
T71611 158-163 VBP denotes share
T4369 164-166 DT denotes an
T95969 167-177 JJ denotes idiopathic
T35011 178-184 NN denotes origin
T94518 184-185 -COMMA- denotes ,
T34533 186-193 VBG denotes ranging
T57537 194-198 IN denotes from
T47481 199-209 JJ denotes autoimmune
T10634 210-219 NNS denotes disorders
T96539 220-222 TO denotes to
T18270 223-230 JJ denotes primary
T92790 231-239 NN denotes antibody
T91348 240-252 NNS denotes deficiencies
T23275 254-258 RB denotes Also
T97483 258-259 -COMMA- denotes ,
T12179 260-264 NNP denotes IVIG
T44219 265-268 VBZ denotes has
T10629 269-274 VBN denotes shown
T45168 275-284 JJ denotes promising
T67208 285-292 NNS denotes results
T77083 293-295 IN denotes in
T72909 296-300 NN denotes case
T84121 301-303 IN denotes of
T92712 304-310 JJ denotes severe
T79863 311-312 -LRB- denotes (
T66824 312-316 JJ denotes such
T43956 317-319 IN denotes as
T9832 320-326 NN denotes sepsis
T13628 326-327 -COMMA- denotes ,
T62406 328-338 NN denotes Parvovirus
T99835 339-342 NN denotes B19
T14835 343-352 NN denotes infection
T15497 352-353 -COMMA- denotes ,
T90831 354-358 NNP denotes West
T76795 359-363 NNP denotes Nile
T72325 364-369 NN denotes virus
T62294 370-382 NN denotes encephalitis
T79163 382-383 -COMMA- denotes ,
T42313 384-387 NN denotes HIV
T73958 387-388 -COMMA- denotes ,
T29310 389-400 NNP denotes Clostridium
T49447 401-410 JJ denotes difficile
T8038 411-421 NNS denotes infections
T10219 421-422 -COMMA- denotes ,
T3443 423-436 NN denotes Mycobacterium
T55185 437-442 NN denotes avium
T2677 442-443 -COMMA- denotes ,
T67405 444-457 NN denotes Mycobacterium
T65630 458-470 NN denotes tuberculosis
T60726 470-471 -COMMA- denotes ,
T52785 472-475 CC denotes and
T44446 476-484 NNP denotes Nocardia
T90848 485-495 NNS denotes infections
T80386 495-496 -RRB- denotes )
T6178 497-500 CC denotes and
T68317 501-510 JJ denotes recurrent
T17705 511-521 NNS denotes infections
T68999 522-524 IN denotes in
T18422 525-532 JJ denotes primary
T52471 533-543 NNS denotes antibodies
T62247 544-556 NNS denotes deficiencies
T55724 557-558 -LRB- denotes [
T27007 558-560 CD denotes 21
T97422 560-561 -RRB- denotes ]
T8813 563-567 JJS denotes Most
T48684 568-576 NNS denotes patients
T37814 577-584 VBP denotes develop
T41895 585-595 NNS denotes antibodies
T32237 596-603 IN denotes against
T55833 604-607 DT denotes the
T23466 608-610 NN denotes NP
T51386 611-614 CC denotes and
T97267 615-618 NN denotes RBD
T48238 619-621 IN denotes of
T17626 622-631 NN denotes 2019-nCoV
T87676 632-638 IN denotes during
T56543 639-642 DT denotes the
T74019 643-649 JJ denotes second
T36179 650-654 NN denotes week
T61939 655-660 IN denotes after
T53819 661-670 NN denotes infection
T47949 671-676 NN denotes onset
T10621 677-678 -LRB- denotes [
T31327 678-680 CD denotes 22
T53799 680-681 -RRB- denotes ]
T76985 683-691 NN denotes Analysis
T6758 692-694 IN denotes of
T88720 695-700 NN denotes serum
T73739 701-708 NNS denotes samples
T20072 709-718 VBD denotes collected
T30704 719-721 CD denotes 14
T66398 722-724 CC denotes or
T43796 725-729 JJR denotes more
T64515 730-734 NNS denotes days
T88119 735-740 IN denotes after
T33297 741-748 NN denotes symptom
T78997 749-754 NN denotes onset
T69102 755-763 VBD denotes revealed
T51393 764-773 NN denotes detection
T49412 774-776 IN denotes of
T86080 777-780 NN denotes IgG
T42365 781-784 CC denotes and
T24248 785-788 NN denotes IgM
T84785 789-799 NNS denotes antibodies
T33598 800-807 IN denotes against
T65176 808-810 NN denotes NP
T29543 811-813 IN denotes in
T67075 814-816 CD denotes 94
T4274 816-817 NN denotes %
T73088 818-821 CC denotes and
T74097 822-824 CD denotes 88
T71868 824-825 NN denotes %
T54079 826-829 CC denotes and
T73098 830-833 NN denotes RBD
T69539 834-836 IN denotes in
T87988 837-840 CD denotes 100
T78691 840-841 NN denotes %
T18580 842-845 CC denotes and
T46489 846-848 CD denotes 94
T64615 848-849 NN denotes %
T60810 850-855 IN denotes among
T38563 856-864 NNS denotes patients
T93829 865-869 IN denotes with
T24980 870-877 NN denotes COVID19
T89545 879-886 NNS denotes Studies
T44838 887-899 RB denotes consistently
T54246 900-904 VBP denotes show
T20581 905-909 IN denotes that
T54967 910-919 VBN denotes increased
T27422 920-934 NN denotes immunoglobulin
T48431 935-941 NNS denotes levels
T7060 942-951 VBP denotes accompany
T92743 952-955 DT denotes the
T24866 956-966 NN denotes transition
T9522 967-971 IN denotes from
T69120 972-977 JJ denotes early
T81312 978-980 TO denotes to
T7048 981-985 JJ denotes late
T25388 986-992 NN denotes course
T44741 993-995 IN denotes of
T20679 996-1003 NN denotes COVID19
T6735 1005-1007 PRP denotes It
T32751 1008-1013 VBZ denotes poses
T41840 1014-1017 DT denotes the
T21434 1018-1029 NN denotes possibility
T75450 1030-1034 IN denotes that
T55251 1035-1039 NN denotes IVIG
T48129 1040-1047 NN denotes therapy
T90120 1048-1053 MD denotes might
T91321 1054-1058 VB denotes help
T89890 1059-1061 TO denotes to
T64443 1062-1072 VB denotes accelerate
T5150 1073-1081 NN denotes recovery
T43666 1082-1086 IN denotes from
T85289 1087-1095 NN denotes COVID-19
R37061 T95212 T56020 arg1Of Hypothesis,4.2.1
R21455 T95212 T84611 arg1Of Hypothesis,:
R41659 T50853 T84611 arg2Of contains,:
R26320 T95417 T50853 arg1Of IVIG,contains
R55634 T83960 T50853 arg2Of pool,contains
R11871 T83960 T65863 arg1Of pool,a
R81126 T83960 T68527 arg1Of pool,large
R87985 T83960 T57480 arg1Of pool,of
R85206 T50450 T57480 arg2Of antibodies,of
R95689 T50450 T98962 arg1Of antibodies,human
R7397 T12037 T52317 arg1Of IVIG,is
R59827 T32201 T52317 arg2Of treatment,is
R45922 T32201 T83276 arg1Of treatment,an
R32666 T32201 T47689 arg1Of treatment,immunomodulatory
R38821 T32201 T26744 arg1Of treatment,currently
R80185 T26744 T6595 arg1Of currently,useful
R62385 T6595 T61951 arg1Of useful,for
R78431 T96672 T61951 arg2Of variety,for
R3964 T96672 T78252 arg1Of variety,a
R72167 T96672 T75647 arg1Of variety,of
R82814 T37666 T75647 arg2Of diseases,of
R55274 T37666 T64366 arg1Of diseases,human
R31515 T37666 T30663 arg1Of diseases,that
R12726 T37666 T71611 arg1Of diseases,share
R20851 T35011 T71611 arg2Of origin,share
R86274 T35011 T4369 arg1Of origin,an
R95215 T35011 T95969 arg1Of origin,idiopathic
R10701 T32201 T94518 arg1Of treatment,","
R19665 T32201 T34533 arg1Of treatment,ranging
R89530 T34533 T57537 arg1Of ranging,from
R77337 T10634 T57537 arg2Of disorders,from
R63281 T10634 T47481 arg1Of disorders,autoimmune
R45693 T34533 T96539 arg1Of ranging,to
R65268 T91348 T96539 arg2Of deficiencies,to
R94792 T91348 T18270 arg1Of deficiencies,primary
R91107 T91348 T92790 arg1Of deficiencies,antibody
R9941 T10629 T23275 arg1Of shown,Also
R28227 T10629 T97483 arg1Of shown,","
R92669 T12179 T44219 arg1Of IVIG,has
R31307 T10629 T44219 arg2Of shown,has
R77637 T12179 T10629 arg1Of IVIG,shown
R23512 T67208 T10629 arg2Of results,shown
R8504 T67208 T45168 arg1Of results,promising
R20697 T67208 T77083 arg1Of results,in
R78894 T72909 T77083 arg2Of case,in
R82064 T72909 T84121 arg1Of case,of
R98709 T6178 T84121 arg2Of and,of
R28624 T52785 T92712 arg1Of and,severe
R80380 T52785 T79863 arg2Of and,(
R24626 T80386 T79863 arg3Of ),(
R19944 T43956 T66824 arg1Of as,such
R49580 T52785 T43956 arg1Of and,as
R37840 T13628 T43956 arg2Of ",",as
R28995 T9832 T13628 arg1Of sepsis,","
R16863 T14835 T13628 arg2Of infection,","
R40263 T14835 T62406 arg1Of infection,Parvovirus
R95673 T14835 T99835 arg1Of infection,B19
R52070 T13628 T15497 arg1Of ",",","
R13275 T62294 T15497 arg2Of encephalitis,","
R22619 T76795 T90831 arg1Of Nile,West
R23224 T62294 T76795 arg1Of encephalitis,Nile
R99263 T62294 T72325 arg1Of encephalitis,virus
R15788 T62294 T79163 arg1Of encephalitis,","
R54321 T42313 T79163 arg2Of HIV,","
R99309 T52785 T73958 arg1Of and,","
R85642 T8038 T29310 arg1Of infections,Clostridium
R55554 T8038 T49447 arg1Of infections,difficile
R94197 T8038 T10219 arg1Of infections,","
R30216 T55185 T10219 arg2Of avium,","
R46944 T55185 T3443 arg1Of avium,Mycobacterium
R36023 T10219 T2677 arg1Of ",",","
R30475 T65630 T2677 arg2Of tuberculosis,","
R32473 T65630 T67405 arg1Of tuberculosis,Mycobacterium
R79700 T52785 T60726 arg1Of and,","
R5424 T2677 T52785 arg1Of ",",and
R82963 T90848 T52785 arg2Of infections,and
R12367 T90848 T44446 arg1Of infections,Nocardia
R36176 T52785 T6178 arg1Of and,and
R5432 T17705 T6178 arg2Of infections,and
R7624 T17705 T68317 arg1Of infections,recurrent
R48790 T6178 T68999 arg1Of and,in
R33893 T62247 T68999 arg2Of deficiencies,in
R41252 T62247 T18422 arg1Of deficiencies,primary
R34450 T62247 T52471 arg1Of deficiencies,antibodies
R24969 T62247 T55724 arg1Of deficiencies,[
R29860 T27007 T55724 arg2Of 21,[
R45347 T97422 T55724 arg3Of ],[
R18045 T48684 T8813 arg1Of patients,Most
R91845 T48684 T37814 arg1Of patients,develop
R13100 T41895 T37814 arg2Of antibodies,develop
R35710 T37814 T32237 arg1Of develop,against
R20807 T51386 T32237 arg2Of and,against
R6800 T51386 T55833 arg1Of and,the
R22109 T23466 T51386 arg1Of NP,and
R81797 T97267 T51386 arg2Of RBD,and
R91140 T51386 T48238 arg1Of and,of
R87740 T17626 T48238 arg2Of 2019-nCoV,of
R8876 T37814 T87676 arg1Of develop,during
R35461 T36179 T87676 arg2Of week,during
R97441 T36179 T56543 arg1Of week,the
R2585 T36179 T74019 arg1Of week,second
R34363 T37814 T61939 arg1Of develop,after
R46687 T47949 T61939 arg2Of onset,after
R33556 T47949 T53819 arg1Of onset,infection
R6993 T37814 T10621 arg1Of develop,[
R3294 T31327 T10621 arg2Of 22,[
R78306 T53799 T10621 arg3Of ],[
R98284 T76985 T6758 arg1Of Analysis,of
R72949 T73739 T6758 arg2Of samples,of
R94093 T73739 T88720 arg1Of samples,serum
R64474 T76985 T20072 arg1Of Analysis,collected
R79737 T64515 T20072 arg2Of days,collected
R31087 T64515 T30704 arg1Of days,14
R58487 T30704 T66398 arg1Of 14,or
R48701 T30704 T43796 arg1Of 14,more
R91116 T20072 T88119 arg1Of collected,after
R29180 T69102 T88119 arg2Of revealed,after
R61094 T78997 T33297 arg1Of onset,symptom
R30751 T78997 T69102 arg1Of onset,revealed
R85646 T51393 T69102 arg2Of detection,revealed
R94930 T51393 T49412 arg1Of detection,of
R15007 T84785 T49412 arg2Of antibodies,of
R35220 T84785 T86080 arg1Of antibodies,IgG
R17029 T86080 T42365 arg1Of IgG,and
R36223 T24248 T42365 arg2Of IgM,and
R4871 T84785 T24248 arg1Of antibodies,IgM
R37373 T51393 T33598 arg1Of detection,against
R80609 T65176 T33598 arg2Of NP,against
R29116 T51393 T29543 arg1Of detection,in
R74727 T54079 T29543 arg2Of and,in
R31620 T4274 T67075 arg1Of %,94
R41074 T71868 T4274 arg1Of %,%
R32415 T4274 T73088 arg1Of %,and
R53047 T74097 T73088 arg2Of 88,and
R60224 T71868 T74097 arg1Of %,88
R30825 T71868 T54079 arg1Of %,and
R92508 T73098 T54079 arg2Of RBD,and
R99739 T54079 T69539 arg1Of and,in
R9744 T64615 T69539 arg2Of %,in
R73124 T78691 T87988 arg1Of %,100
R67370 T64615 T78691 arg1Of %,%
R15728 T78691 T18580 arg1Of %,and
R74845 T46489 T18580 arg2Of 94,and
R42305 T64615 T46489 arg1Of %,94
R38001 T51393 T60810 arg1Of detection,among
R89986 T38563 T60810 arg2Of patients,among
R54593 T38563 T93829 arg1Of patients,with
R6445 T24980 T93829 arg2Of COVID19,with
R86911 T54246 T44838 arg1Of show,consistently
R41127 T89545 T54246 arg1Of Studies,show
R52555 T7060 T54246 arg2Of accompany,show
R1890 T7060 T20581 arg1Of accompany,that
R15150 T48431 T54967 arg2Of levels,increased
R79272 T48431 T27422 arg1Of levels,immunoglobulin
R9994 T48431 T7060 arg1Of levels,accompany
R27595 T24866 T7060 arg2Of transition,accompany
R10059 T24866 T92743 arg1Of transition,the
R64970 T24866 T9522 arg1Of transition,from
R11593 T25388 T9522 arg2Of course,from
R11280 T7048 T69120 arg1Of late,early
R61089 T7048 T81312 arg1Of late,to
R36970 T25388 T7048 arg1Of course,late
R76248 T25388 T44741 arg1Of course,of
R16578 T20679 T44741 arg2Of COVID19,of
R93295 T6735 T32751 arg1Of It,poses
R68469 T21434 T32751 arg2Of possibility,poses
R17888 T21434 T41840 arg1Of possibility,the
R71902 T91321 T21434 arg2Of help,possibility
R4510 T91321 T75450 arg1Of help,that
R34056 T48129 T55251 arg1Of therapy,IVIG
R30440 T48129 T90120 arg1Of therapy,might
R46659 T91321 T90120 arg2Of help,might
R94505 T48129 T91321 arg1Of therapy,help
R59227 T64443 T91321 arg2Of accelerate,help
R39248 T64443 T89890 arg1Of accelerate,to
R27615 T48129 T64443 arg1Of therapy,accelerate
R41612 T5150 T64443 arg2Of recovery,accelerate
R13579 T5150 T43666 arg1Of recovery,from
R80924 T85289 T43666 arg2Of COVID-19,from

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T135 231-239 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T136 384-387 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T137 695-700 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T138 777-780 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T139 785-788 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T140 920-934 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T119 199-219 Disease denotes autoimmune disorders http://purl.obolibrary.org/obo/MONDO_0007179
T120 223-252 Disease denotes primary antibody deficiencies http://purl.obolibrary.org/obo/MONDO_0015517
T121 343-352 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T122 364-382 Disease denotes virus encephalitis http://purl.obolibrary.org/obo/MONDO_0006009
T123 389-421 Disease denotes Clostridium difficile infections http://purl.obolibrary.org/obo/MONDO_0000705
T124 458-470 Disease denotes tuberculosis http://purl.obolibrary.org/obo/MONDO_0018076
T125 476-495 Disease denotes Nocardia infections http://purl.obolibrary.org/obo/MONDO_0017776
T126 511-524 Disease denotes infections in http://purl.obolibrary.org/obo/MONDO_0005550
T127 525-556 Disease denotes primary antibodies deficiencies http://purl.obolibrary.org/obo/MONDO_0015517
T128 661-670 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T129 870-877 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T130 996-1003 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T131 1087-1095 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T4 199-219 Phenotype denotes autoimmune disorders http://purl.obolibrary.org/obo/HP_0002960
T5 320-326 Phenotype denotes sepsis http://purl.obolibrary.org/obo/HP_0100806
T6 370-382 Phenotype denotes encephalitis http://purl.obolibrary.org/obo/HP_0002383
T7 501-521 Phenotype denotes recurrent infections http://purl.obolibrary.org/obo/HP_0002719
T8 910-941 Phenotype denotes increased immunoglobulin levels http://purl.obolibrary.org/obo/HP_0010702

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T142 0-65 Sentence denotes 4.2.1 Hypothesis: IVIG contains a large pool of human antibodies
T143 66-253 Sentence denotes IVIG is an immunomodulatory treatment currently useful for a variety of human diseases that share an idiopathic origin, ranging from autoimmune disorders to primary antibody deficiencies.
T144 254-562 Sentence denotes Also, IVIG has shown promising results in case of severe (such as sepsis, Parvovirus B19 infection, West Nile virus encephalitis, HIV, Clostridium difficile infections, Mycobacterium avium, Mycobacterium tuberculosis, and Nocardia infections) and recurrent infections in primary antibodies deficiencies [21].
T145 563-682 Sentence denotes Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22].
T146 683-878 Sentence denotes Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19.
T147 879-1004 Sentence denotes Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19.
T148 1005-1096 Sentence denotes It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T4 199-219 Phenotype denotes autoimmune disorders http://purl.obolibrary.org/obo/HP_0002960
T5 320-326 Phenotype denotes sepsis http://purl.obolibrary.org/obo/HP_0100806
T6 370-382 Phenotype denotes encephalitis http://purl.obolibrary.org/obo/HP_0002383
T7 501-521 Phenotype denotes recurrent infections http://purl.obolibrary.org/obo/HP_0002719
T8 910-941 Phenotype denotes increased immunoglobulin levels http://purl.obolibrary.org/obo/HP_0010702